Biopharmaceutical company secures funding for skin disease treatments
- Azitra plans to raise approximately $10.5 million.
- The financing could total around $20.9 million with additional shares.
- Funding will support the company's skin disease treatments.
Azitra Inc., a biopharmaceutical company focused on developing innovative treatments for skin diseases, has priced a private placement financing aimed at raising up to approximately $10.5 million. The financing could potentially bring in an additional approximate $20.9 million with further shares. This funding is part of Azitra's efforts to advance its clinical programs.
The financing involves the issuance of shares of common stock and warrants to purchase shares of common stock to accredited investors. Azitra aims to use the net proceeds from this financing to support the development of its skin disease treatments, which are in various stages of clinical research. This strategic financial move reflects the company's commitment to expanding its clinical capabilities and advancing its research initiatives.
